Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICD Scrutiny: Study Quantifies Significant Off-Guideline Implant Activity

This article was originally published in The Gray Sheet

Executive Summary

The implantable defibrillator sector took another potential hit last week with findings that more than 20% of patients treated with the devices for primary prevention of sudden cardiac death should not receive them under current guidelines.

You may also be interested in...

51 More Hospitals Join Federal ICD Settlement

The Department of Justice says the additional 51 hospitals that settled with the government on charges of billing for ICD implants outside of Medicare coverage guidelines represent the "final stage" of a long-running investigation. DoJ previously identified another 457 hospitals that have settled. Hospitals payments tied to the investigation total $273 million.

Hospitals Settle Federal Allegations Of ICDs Implanted Afoul Of Medicare Policy

More than 400 hospitals settled with the Justice Department following a five-plus year investigation into ICD implants performed during post-heart attack and post-surgery periods when Medicare policy states the devices generally should not be put in.

AHRQ Tech Assessment Supports Primary Prevention Implantable Defibrillators

The agency affirms the evidence in favor of implantable defibrillators for primary prevention of sudden cardiac death is strong for patients with reduced left-ventricular ejection fraction, but does not support resynchronization ICDs for this population.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts